Table 3.
Clinical parameters associated with neoadjuvant chemotherapy response
| Variable | No. of patients | Responders n (%) | Non responders n (%) | p value | ||
|---|---|---|---|---|---|---|
| CR+PR | ST+PD | |||||
| FIGO stage | ||||||
| IIB | 67 | 37 (55.2) | 30 (44.8) | 0.70 | ||
| IIIA | 87 | 52 (59.8) | 35 (40.2) | |||
| IIIB | 53 | 28 (47.2) | 25 (47.2) | |||
| Tumor size (baseline) | ||||||
| ≤ 4 cm | 107 | 67 (62.6) | 40 (37.4) | 0.07 | ||
| > 4 cm | 100 | 50 (50) | 50 (50) | |||
| Age | ||||||
| ≤ 44 years | 54 | 24 (44.4) | 30 (55.6) | 0.04 | ||
| > 44 years | 153 | 93 (60.8) | 60 (39.2) | |||
| Hb level (initial) | ||||||
| ≤ 12 mg/dl | 39 | 16 (41) | 23 (59) | 0.03 | ||
| > 12 mg/dl | 168 | 101 (60.1) | 67 (39.9) | |||
| Neoadjuvant chemotherapy regimen | ||||||
| Paclitaxel + Carboplatin | 177 | 106 (59.9) | 71 (40.1) | 0.02 | ||
| Topotecan + Cisplatin | 30 | 11 (36.7) | 19 (63.6) | |||
| NACT No.of cycles | ||||||
| 1-2 cycles | 81 | 37 (45.7) | 44 (54.3) | 0.01 | ||
| 3-4 cycles | 126 | 80 (63.5) | 46 (36.5) | |||
| Histological type | ||||||
| Squamous cell carcinoma | 182 | 107 (58.8) | 75 (41.2) | 0.08 | ||
| Adenocarcinoma | 25 | 10 (40) | 15 (60) | |||
| Cervical boost | ||||||
| BT | 62 | 39 (62.9) | 23 (37.1) | 0.53 | ||
| Arch technique | 20 | 11 (55) | 9 (45) | |||
| 3 | 2 (66.7) | 1 (33.3) | ||||